Ferritin, C‐Reactive Protein, and Soluble <scp>CD25</scp> Distinguish <scp>TAFRO</scp> From <scp>HLH</scp>
A clinical pathway for differentiating TAFRO from HLH when a cytokine storm is identified, using ferritin, C-reactive protein, and soluble CD25.
Authors
- Lusia Sepiashvili
- Joshua D. Brandstadter (ORCID: https://orcid.org/0000-0003-0652-5791)
- Marley Blommers
- Steven Rowe
- Mariam Goubran (ORCID: https://orcid.org/0000-0002-9181-379X)
- David C. Fajgenbaum (ORCID: https://orcid.org/0000-0002-7367-8184)
- Bridget Austin
- Saishravan Shyamsundar (ORCID: https://orcid.org/0000-0002-0160-8910)
- Lisa K. Peterson (ORCID: https://orcid.org/0000-0001-8702-1311)
- Mateo Sarmiento Bustamante (ORCID: https://orcid.org/0009-0002-6774-2714)
- Luke Y. C. Chen (ORCID: https://orcid.org/0000-0002-9551-2951)
- André Mattman (ORCID: https://orcid.org/0000-0001-8629-2419)
- Junyan Shi (ORCID: https://orcid.org/0000-0001-5620-6831)
- Kathleen W. McNicholas
Institutions
- Dalhousie University (CA)
- Memorial University of Newfoundland (CA)
- University of British Columbia (CA)
- Hospital for Sick Children (CA)
- St. Paul's Hospital (CA)
- Vancouver General Hospital (CA)
- ARUP Laboratories (United States) (US)
- St. Paul's Hospital (CA)
- University of Pennsylvania (US)
Publication Details
- Journal
- American Journal of Hematology
- Published
- 2025-09-26
- DOI
- https://doi.org/10.1002/ajh.70081
- Citations
- 2
- Primary Topic
- Autoimmune and Inflammatory Disorders Research
- Type
- article
- Field-Weighted Citation Impact
- 3.54
Funders
- University of Pennsylvania
- Clinton Foundation
- Recordati Rare Diseases
- U.S. Food and Drug Administration
- National Heart, Lung, and Blood Institute